Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics

Autor: Vivek Purohit, Yeamin Huh, Jessica Wojciechowski, Anna Plotka, Stephanie Salts, Jeremias Antinew, Angela Dimitrova, Timothy Nicholas

Publikováno v: The AAPS Journal. 25

Abstract Ritlecitinib is a selective, covalent, irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases. Pharmacokinetics and safety of ritlecitinib in participants with hepat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e24e96db6c84e9afb40a874f86a4edf6
https://doi.org/10.1208/s12248-023-00792-8

Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib

Autor: Jessica, Wojciechowski, Bimal K, Malhotra, Xiaoxing, Wang, Luke, Fostvedt, Hernan, Valdez, Timothy, Nicholas

Publikováno v: British Journal of Clinical Pharmacology. 88:3856-3871

Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate-to-severe atopic dermatitis. Herein we describe the time-course of drug-induced platelet reduction following abrocitinib administration, identify covariates affecting p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e8274614bd4531f07ec74fa6928599
https://doi.org/10.1111/bcp.15334

Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Autor: Jessica Wojciechowski, Vivek S. Purohit, Lutz O. Harnisch, Pinky Dua, Beesan Tan, Timothy Nicholas

Publikováno v: Clinical pharmacology and therapeutics. 112(6)

Myostatin, a negative regulator of skeletal muscle growth, is a therapeutic target in muscle-wasting diseases. Domagrozumab, a humanized recombinant monoclonal antibody, binds myostatin and inhibits activity. Domagrozumab was investigated in a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5eb6de180f0518a148671b168c946e8
https://pubmed.ncbi.nlm.nih.gov/36104012

Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring

Autor: Jessica Wojciechowski, Deborah Marriott, Indy Sandaradura, Richard O. Day, Stephanie E. Reuter, Sophie L. Stocker

Publikováno v: Antimicrob Agents Chemother

Fluconazole has been associated with higher mortality compared with the echinocandins in patients treated for invasive candida infections. Underexposure from current fluconazole dosing regimens may contribute to these worse outcomes, so alternative d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e4d7ed223fbe0c676f0c736fde90bb
https://pubmed.ncbi.nlm.nih.gov/33361309

Pharmacokinetics-Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease

Autor: Diane R. Mould, Richard N. Upton, Jessica Wojciechowski

Publikováno v: Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases ISBN: 9781119289234
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

This chapter explains the rational behind the concept of pharmacokinetics‐guided dosing and dashboards, and the expected benefit of dashboards in improving therapy with monoclonal antibodies in inflammatory disease. It outlines a brief description

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b591049c03d48ec7ed51f6b538610b
https://doi.org/10.1002/9781119289234.ch12